Education - In my estimation, there have been approximately 114 PDUFA decisions relating to NDA/BLA and sNDA/sBLA’s in 2012. Of these, 97 applicants received drug approvals and … Continue Reading
Read NowLong Ideas - Just over a week has passed since our last report on Pharmacyclics (PCYC), in which we argued that the stock has solid upside potential based … Continue Reading
Read NowLong Ideas - Shares of Questcor Pharmaceuticals (QCOR) have started to rise to more realistic valuations in the new year (as PropThink expected), breaking $31 dollars on Tuesday … Continue Reading
Read NowLong Ideas - Shares of Chelsea Therapeutics (CHTP) opened sharply higher on news Wednesday that FDA has provided the company with a new pathway for approval of Northera. … Continue Reading
Read NowLong Ideas - PropThink’s first story of the week turned into a whopping 24% gainer by Friday’s close. We iterated our enthusiasm for Pharmacyclics (PCYC) on Monday, following … Continue Reading
Read NowMost Popular - Shares of ResMed Inc. (RMD) have finally found their top, peaking at $48.37 in late January before dropping to the $43 level. But the downslide … Continue Reading
Read NowMost Popular - IMUC proved a successful trade in the short-term, climbing 34% since our report was published on the first of the month. In early trials, lead … Continue Reading
Read Now